Business Context and Reporting Period
Company: Guardian Pharmacy Services, Inc. (GRDN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Guardian is a leading pharmacy services provider specializing in technology-enabled services for residents of long-term care facilities (LTCFs), with a primary focus on assisted living facilities (ALFs) and behavioral health facilities (BHFs). As of December 31, 2025, the company operated 61 pharmacies (54 full-service) serving approximately 205,000 residents across 8,400 LTCFs in 38 states. The company completed its IPO in September 2024 and a follow-on offering in May 2025.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2025 |
|---|---|---|
| Revenues | $1,228,409 | $1,448,685 |
| Cost of Goods Sold | $984,038 | $1,155,967 |
| Gross Profit | $244,371 | $292,718 |
| Gross Margin | 19.9% | 20.2% |
| Operating Income (Loss) | $(62,920) | $72,701 |
| Net Income (Loss) | $(71,033) | $48,958 |
| Net Income Attributable to Guardian | $(110,047) | $49,219 |
| Adjusted EBITDA | $90,834 | $115,145 |
| Cash and Cash Equivalents (Year End) | $4,660 | $65,619 |
| Operating Cash Flow | $57,960 | $100,255 |
| Debt Outstanding | $0 | $0 |
Note: 2024 GAAP net loss was significantly impacted by a one-time $125.7 million share-based compensation charge related to the Corporate Reorganization and IPO.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.9% year-over-year to $1.45 billion. This was driven by $151.9 million in organic growth (increased resident count from 186,000 to 205,000 and prescription volume growth) and $68.4 million from acquisitions.
- Profitability Turnaround: The company moved from an operating loss of $62.9 million in 2024 to an operating income of $72.7 million in 2025. This shift was primarily due to the absence of the significant non-recurring share-based compensation expense recorded in 2024.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 28.4% to $220.0 million, largely due to the $117.6 million reduction in share-based compensation. Adjusted SG&A as a percentage of revenue remained stable at 13.7%.
- Liquidity Improvement: Cash and cash equivalents increased from $4.7 million to $65.6 million, bolstered by strong operating cash flows ($100.3 million) and the absence of debt repayments (the Term Loan was paid off in December 2024).
- Acquisitions: The company completed various pharmacy acquisitions in 2025 with a total preliminary purchase consideration of $16.9 million, adding $40.1 million in revenue for the year.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management emphasizes a growth strategy focused on increasing the number of residents served through organic growth (new residents, increased adoption rates) and acquisitions. The company targets the ALF and BHF sectors, which represent over two-thirds of revenue, citing aging demographics and increasing acuity of residents as key tailwinds. The company maintains a "high-touch" service model supported by proprietary technology (GuardianShield and Guardian Compass) to drive adherence and reduce costs for payors.
Key Risks and Contingencies:
- Regulatory & Reimbursement: Significant exposure to changes in Medicare Part D and Medicaid reimbursement rates. The Inflation Reduction Act (IRA) and potential executive actions on drug pricing could reduce profitability. The company is subject to strict CMS regulations for Part D Network LTC Pharmacy providers.
- Competition: The market is highly competitive with national providers (e.g., Omnicare, PharMerica) and local pharmacies. "Freedom of choice" laws in some states allow residents to select their pharmacy, increasing churn risk.
- Operational Risks: Dependence on senior management and local pharmacy operators. Labor shortages and inflationary pressures on labor costs could impact margins. Cybersecurity threats and data breaches pose operational and reputational risks.
- Legal & Compliance: Subject to federal and state fraud and abuse laws (Anti-Kickback Statute, False Claims Act). The company faces ongoing audits and potential whistleblower complaints.
Investor Verification Checklist
- Recurring Expenses: Verify the sustainability of the 2025 profit margin by confirming that the $13.9 million share-based compensation expense in 2025 is representative of future periods, excluding the $125.7 million one-time charge from 2024.
- Organic Growth Metrics: Confirm the reported increase in resident count (186k to 205k) and prescription volume (25.1M to 28.6M) to validate the organic revenue growth claim.
- Reimbursement Rates: Monitor CMS guidance and state Medicaid policies regarding reimbursement rates for institutional pharmacies, particularly regarding the "donut hole" and inflation rebates under the IRA.
- Acquisition Integration: Review the performance of 2025 acquisitions to ensure they are meeting projected EBITDA margins and integration synergies within the expected 48-month timeframe.
- Debt Capacity: Note that while the company currently has no debt outstanding, it maintains a $40 million line of credit (expandable to $75 million) maturing in 2027. Assess future capital needs for M&A against this facility.